Virtus Biotech ETF

BBP

시가총액 US$1.25억

Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.

Virtus Biotech ETF (BBP) is rated a buy for its focused exposure to FDA-approved biotech firms and strong recent outperformance. BBP's equal-weight, quarterly rebalancing strategy efficiently captures upside from breakout holdings like MRNA while reducing speculative risk. Rising sector deal activity and GLP-1 market expansion underpin a favorable outlook for BBP despite macro headwinds like higher interest rates.

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

After a 50%+ run from lows last April through highs in mid-January, the Biotech group has been trending sideways over the last few months. Biotech hasn't garnered much attention lately, with all the coverage of the Iran War and the AI Doom trade that's been taking down software stocks even as AI infrastructure stocks continue to surge.

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?

We have highlighted four top-performing ETFs from different sectors that have led the way in June.

The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.